Updates in the Treatment of HR+ Breast Cancer - Episode 4

Expert Perspectives on Optimizing Biomarker Testing in Advanced HR+/HER2- Breast Cancer

, , ,

A panel of experts give perspectives on optimizing biomarker testing in Advanced HR+/HER2- Breast Cancer.

EP. 1: Expert Insights on Biomarker Testing in Early-Stage Breast Cancer
EP. 2: Insights from TAILORx and RxPONDER in Guiding Treatment in Early-Stage HR+ Breast Cancer
EP. 3: Advancements in Adjuvant Therapy in Early-Stage HR+ Breast Cancer
Now Viewing
EP. 4: Expert Perspectives on Optimizing Biomarker Testing in Advanced HR+/HER2- Breast Cancer
EP. 5: Potential With Individual Tumor Sequencing With Bespoke Testing Methodologies and ctDNA
EP. 6: Updates in Treatment Approaches With CDK4/6 Inhibitors in HR+ Breast Cancer
EP. 7: Expert Perspectives in Navigating Treatment Strategies with CDK4/6 Inhibitors in HR+ Breast Cancer
EP. 8: Navigating 2L Treatment Strategies with Oral SERDs and Elasestrant
EP. 9: Treatment Advancements Targeting the PI3K/AKT Pathway in HR+ Breast Cancer
EP. 10: ADC-Based Treatment Strategies HR+Breast Cancer:Updates from DESTINY-Breast06
EP. 11: Expert Perspectives in Sequencing ADC-Based Therapies in HR+ Breast Cancer
EP. 12: Looking Ahead: Expert Future Perspectives in the HR+ Breast Cancer Landscape

Video content above is prompted by the following:

  • For a patient whose cancer has progressed, do you obtain a new biopsy or go back to the original sample? Why?
  • What biomarkers do you test for in advanced-stage breast cancer and when? Is there a need for NGS testing before first-line metastatic disease? (eg, BRCA, PIK3CA, PD-L1, NTRK, MSI-H/dMMR, TMB-H)